Aaron's questions to Quest Diagnostics Inc (DGX) leadership • Q2 2025
Question
Aaron, on for Michael Ryskin at Bank of America, requested an update on the Haystack MRD test, including feedback from oncologists and the overall progress of its market adoption.
Answer
CEO James Davis reported 'good progress' with the Haystack test, highlighting a 'really nice conversion' rate from its early experience program to full-time customers. He stated that feedback from oncologists has been very positive, with physicians recognizing the test's superior sensitivity, turnaround time, and the personal service provided by Quest's client team. He expects significant growth to continue.